BioMarin began workforce consolidation at Amicus’ headquarters in Princeton, New Jersey after completing its $4.8 billion acquisition of Amicus Therapeutics for rare disease medicines. A WARN filing indicates 58 roles tied to the Amicus HQ will be eliminated starting in August, with terminations expected to conclude around end of October. BioMarin said the cuts reflect organizational overlap and that the integration effort will leverage BioMarin’s global scale, manufacturing capabilities, and commercial reach to bring Amicus therapies to more Fabry and Pompe patients worldwide. The company did not specify whether Princeton will remain an ongoing site beyond the integration window. BioMarin also highlighted pipeline value gained through the transaction, including access to DMX-200 in phase 3 development for focal segmental glomerulosclerosis. For investors and operational leaders, the immediate impact is cost restructuring and integration execution risk, while longer-term impact hinges on seamless manufacturing, commercialization continuity, and development alignment across overlapping programs.